📣 Presidential Symposium Spotlight 📣: Head-to-head vs sotorasib or adagrasib, divarasib improved PFS (9.8 vs 5.7 mo; HR, 0.58) and OS (HR, 0.56) in previously treated KRAS G12C–mutated NSCLC in the phase 3 Krascendo 1 trial.

Full @myESMO #ESMO26 data: https://onclive.com/view/divarasib-improves-pfs-and-os-vs-sotorasib-or-adagrasib-in-pretreated-kras-g12c-mutated-nsclc

#lcsm #medtwitter #oncology @UTMDAnderson